{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-unidentified-cause/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"d41b619e-ef9e-59b6-876b-0b3d52f0884a","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field ce726f98-f04a-4b92-b3ea-a77c01420bce --><h2>Clarithromycin</h2><!-- end field ce726f98-f04a-4b92-b3ea-a77c01420bce -->","summary":"","htmlStringContent":"<!-- begin item 2d53075d-65fd-4eea-a687-a77c01414252 --><!-- end item 2d53075d-65fd-4eea-a687-a77c01414252 -->","topic":{"id":"f89632d0-8e52-59da-bd63-555a73aa134f","topicId":"ac596995-c452-4bf5-81bf-0aea66eca309","topicName":"Dyspepsia - unidentified cause","slug":"dyspepsia-unidentified-cause","lastRevised":"Last revised in October 2018","chapters":[{"id":"9fdd530d-f12b-5642-954b-6284524a3fdb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4ac2b712-5571-56ca-9ac4-25c9e354a821","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16fcbe75-c057-5b25-8039-9145eb897f12","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"be6e1eb9-7eb4-54b8-980d-7a18a90127c3","slug":"changes","fullItemName":"Changes"},{"id":"8eb7dbc2-40da-5433-b290-44902a364d61","slug":"update","fullItemName":"Update"}]},{"id":"a44ffd66-34ee-565e-8b89-d09f62dd9656","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ad917944-2a8c-561c-ba7d-5e5c7ea860e4","slug":"goals","fullItemName":"Goals"},{"id":"cbb4bad0-1dbe-5c62-9adc-bb1a65fe6381","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"54d592f8-f244-5cc8-aed5-81cb136af042","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca8a0b2-46c5-52c2-a05d-1ae84806cefd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5e33c66-dee5-57d8-9eff-828ad855e204","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"eff9b41a-cac2-5b9a-8614-2486d8206ffd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4dfc51d9-1416-5432-bc80-019f5708238c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec8766af-6b0a-5a4d-8897-2e3ba2af658d","slug":"definition","fullItemName":"Definition"},{"id":"e1cbef45-8ac7-5376-a1d2-c5d0a2cc924b","slug":"causes","fullItemName":"Causes"},{"id":"c7487dda-a4e1-5d9e-bc96-e583302af12c","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"0eb82dd3-e433-5b8e-a8d9-46987aab8940","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2acef31-cf6d-5e3e-b2e0-99bc02684183","slug":"assessment","fullItemName":"Assessment"},{"id":"86ebd63c-3596-5ac0-9cd3-4a312bb2d7e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f244ecd9-294a-5fa3-9b22-a2e8f2ae408c","fullItemName":"Management","slug":"management","subChapters":[{"id":"bafb1a12-7cf3-5c6c-921a-03d86efd995d","slug":"dyspepsia-unidentified-cause","fullItemName":"Scenario: Dyspepsia - unidentified cause"}]},{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2978bf31-384a-5964-bba7-5ca72e2a700a","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"a51b3918-0bed-5c45-887b-a5d3e5fd3031","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"8579e41d-876a-5f82-9cb8-04675dce1bb3","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"d41b619e-ef9e-59b6-876b-0b3d52f0884a","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"9ea259a4-6c7f-524f-8866-6164a9696c25","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"640d4b46-3f9c-5cef-aeda-9a374a03fae8","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"fe5b2b68-8d84-5867-bc39-c63cbcd815f8","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"0857fa25-e261-5ecd-b851-fbe52518072d","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"210b1a7b-a0e0-558a-acbe-539f538e840d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0e0cffca-8140-5660-bd87-d4288485522f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4726f06d-25b6-56d1-83c0-3d729c2bb571","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"301b4d9b-8d13-5cc1-8e9a-f8f68c4fa019","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5e963a22-e16a-5e4a-b7a9-072decaccaa1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1d047d4-3011-5ca0-955c-b366ab2a9fb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cd5de0cc-ba55-5ad9-b09b-3025cc68334c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc0ebb19-4869-5b31-8bcf-f0b6e5af54db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ee68679c-64c6-54ac-a78e-c681c26b4374","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6895548b-a79b-401d-aaac-a77c0141622c --><h3>Contraindications and cautions</h3><!-- end field 6895548b-a79b-401d-aaac-a77c0141622c -->","summary":"","htmlStringContent":"<!-- begin item aa72f30a-4454-45a6-aad1-a77c01415de3 --><!-- begin field 885459a9-847f-4141-82d3-a77c0141622c --><ul><li><strong>Do not prescribe clarithromycin to people with:</strong><ul><li>Severe hepatic impairment in combination with renal impairment.</li><li>Hypokalaemia — risk of prolongation of the QT interval.</li><li>A history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li></ul></li><li><strong>Prescribe clarithromycin with caution to people with:</strong><ul><li>Impaired hepatic function (or people concomitantly taking potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been reported rarely.</li><li>Chronic kidney disease (CKD) stages 4 and 5 — if the estimated glomerular filtration rate (eGFR) is less than 30 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal dose, and avoid Klaricid XL<sup>®</sup> or clarithromycin M/R preparations.</li><li>Coronary heart disease, severe cardiac insufficiency, hypomagnesaemia, or bradycardia (heart rate less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Myasthenia gravis — may aggravate symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field 885459a9-847f-4141-82d3-a77c0141622c --><!-- end item aa72f30a-4454-45a6-aad1-a77c01415de3 -->","subChapters":[]},{"id":"34742afb-90ea-5604-aa41-0e742d2c3152","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 0e44418a-e2e4-4904-bc94-a77c01418088 --><h3>Adverse effects</h3><!-- end field 0e44418a-e2e4-4904-bc94-a77c01418088 -->","summary":"","htmlStringContent":"<!-- begin item d3adc0d1-59df-42dd-a044-a77c01417e78 --><!-- begin field 506800c1-d814-41f7-ac0f-a77c01418088 --><ul><li>The most common adverse effects of clarithromycin include mild nausea, vomiting, abdominal discomfort, and diarrhoea.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Taste disturbance, headache, insomnia, and hyperhidrosis have also been reported.</li><li>Hepatotoxicity (including cholestatic jaundice) and rash are reported less frequently.</li><li>Other adverse effects reported rarely or very rarely include pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li><li>Anaphylaxis is rarely associated with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field 506800c1-d814-41f7-ac0f-a77c01418088 --><!-- end item d3adc0d1-59df-42dd-a044-a77c01417e78 -->","subChapters":[]},{"id":"15970adc-49b6-53df-9ee1-1dc15928a226","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a4b03a7d-ad27-4024-8ab9-a77c0141c5f8 --><h3>Drug interactions</h3><!-- end field a4b03a7d-ad27-4024-8ab9-a77c0141c5f8 -->","summary":"","htmlStringContent":"<!-- begin item b783bca3-c0e7-484c-a5f6-a77c0141c313 --><!-- begin field 9fc94064-693e-430b-a3f1-a77c0141c5f8 --><h4>Possible drug interactions with clarithromycin include:</h4><ul><li><strong>Carbamazepine </strong>— clarithromycin increases the plasma concentration of carbamazepine. Consider reducing the dose of carbamazepine by 30–50% during treatment with clarithromycin. Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li><li><strong>Colchicine </strong>— clarithromycin possibly increases the risk of colchicine toxicity. Stop or reduce the dose of colchicine, and avoid concomitant use is renal or hepatic impairment.</li><li><strong>Drugs that prolong the QT interval</strong> (such as anti-arrhythmics like amiodarone and sotalol, antipsychotics like amisulpride, and tricyclic antidepressants) — seek advice from a medical microbiologist regarding a suitable alternative antibiotic. Macrolides can also prolong the QT interval, increasing the risk of arrhythmias such as Torsades de pointes, and concomitant use of drugs that prolong the QT interval is not recommended.</li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists) — seek advice from a medical microbiologist regarding a suitable alternative antibiotic. Hypokalaemia is a risk factor for QT prolongation.</li><li><strong>Itraconazole </strong>— clarithromycin increases the plasma concentration of itraconazole.</li><li><strong>Ketoconazole</strong> — the manufacturer advises to avoid the use of concomitant clarithromycin in severe renal impairment.</li><li><strong>Mirabegron</strong> — when given with clarithromycin, avoid or reduce the dose of mirabegron in renal or hepatic impairment.</li><li><strong>Omeprazole </strong>— the plasma concentrations of both drugs are increased when clarithromycin is given with omeprazole.</li><li><strong>Phenytoin </strong>— clarithromycin inhibits the metabolism of phenytoin, leading to increased plasma concentrations. If there are signs of phenytoin toxicity, such as blurred vision, nystagmus, ataxia, or drowsiness, stop clarithromycin and seek specialist advice if needed.</li><li><strong>Sildenafil </strong>— clarithromycin increases the plasma concentration of sildenafil. Consider reducing the initial dose for sildenafil.</li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — avoid concomitant use, as simvastatin is extensively metabolized by CYP3A4. If clarithromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin — avoid concurrent use with clarithromycin as atorvastatin is moderately metabolized by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (that is 10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism, therefore interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Theophylline </strong>— clarithromycin possibly increases the plasma concentration of theophylline. Consider a dose reduction of theophylline if toxicity is suspected (for example headache, nausea, or palpitations occur).</li><li><strong>Quetiapine </strong>— clarithromycin possibly increases the plasma concentration of quetiapine. The manufacturer of quetiapine advises to avoid concomitant use.</li><li><strong>Warfarin </strong>— clarithromycin enhances the anticoagulant effect of warfarin, and occasionally this may be a marked effect. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Antidiabetic drugs </strong>— the concurrent use of clarithromycin and antidiabetic drugs (such as nateglinide and repaglinide) can result in significant hypoglycaemia. Monitor blood glucose levels more regularly and adjust the antidiabetic drug dose accordingly.</li><li><strong>Calcium channel blockers (CCBs) </strong>— clarithromycin possibly inhibits the metabolism of CCBs, increasing the risk of adverse effects such as hypotension.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field 9fc94064-693e-430b-a3f1-a77c0141c5f8 --><!-- end item b783bca3-c0e7-484c-a5f6-a77c0141c313 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}